...
首页> 外文期刊>Molecular medicine reports >Release characteristics of bone-like hydroxyapatite/poly amino acid loaded with rifapentine microspheres in vivo
【24h】

Release characteristics of bone-like hydroxyapatite/poly amino acid loaded with rifapentine microspheres in vivo

机译:骨样羟基磷灰石/聚氨基酸的释放特性加载二兆内微球的体内

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Bone-like hydroxyapatite/poly amino acid (BHA/PAA) is a potential bone repair material. Rifapentine-loaded poly(lactic-co-glycolic acid) microspheres (RPMs) are bioactive and efficient controlled-release delivery systems used in vitro. The aim of the present study was to investigate the in vivo drug release characteristics of RPM-loaded BHA/PAA on a rabbit model of bone defect. RPM was combined with BHA/PAA to obtain the drug-loaded, slow-releasing bioactive material. Bone defects were generated in New Zealand white rabbits and the rabbits were then implanted with RPM-loaded BHA/PAA. High-performance liquid chromatography (HPLC) was used to determine the concentrations of rifapentine in the plasma and the local muscle tissues of the treated rabbits. Hematoxylin and eosin (H&E) staining and biochemical analyses were performed to elucidate potential side effects of RPM-loaded BHA/PAA on the heart, liver and kidney histopathology and functions of the treated rabbits. The biocompatibility and osteogenic ability of RPM-loaded BHA/PAA was evaluated by H&E staining. The results demonstrated that the material was completely degraded and absorbed at 12 weeks following implantation and new trabecular bone and cartilage tissues had formed. The in vivo release tests revealed that RPM-loaded BHA/PAA exhibited sustained release profiles of rifapentine and the drug concentration in the muscle tissues remained higher than the minimum inhibitory concentration of rifapentine against Mycobacterium tuberculosis for as long as 12 weeks. In addition, RPM-loaded BHA/PAA had no long-term side effects to the heart, liver and kidney of the treated rabbits. In conclusion, the present study demonstrated that RPM-loaded BHA/PAA slowly and continuously released rifapentine in vivo and exhibited no side effects on heart, liver and kidney tissues and function. Furthermore, RPM-loaded BHA/PAA promoted new bone formation, while it was gradually degraded and absorbed. The present study provided a theoretical basis for the potential advancement in developing novel treatments for osteoarticular tuberculosis.
机译:骨样羟基磷灰石/聚氨酯(BHA / PAA)是潜在的骨修复材料。加载二兆内的聚(乳酸 - 共乙醇酸)微球(RPMS)是体外使用的生物活性和有效的控制释放递送系统。本研究的目的是研究RPM加载的BHA / PAA的体内药物释放特征对骨缺损的兔模型。 RPM与BHA / PAA相结合,得到药物负载,缓慢释放的生物活性材料。在新西兰白兔中产生骨缺陷,然后用RPM加载的BHA / PAA植入兔子。使用高效液相色谱(HPLC)来确定血浆中二兆内的浓度和治疗的兔的局部肌肉组织。进行血清素和曙红(H&E)染色和生物化学分析,以阐明RPM负载的BHA / PAA对心脏,肝肾组织病理学和治疗兔的功能的潜在副作用。通过H&E染色评价RPM负载BHA / PAA的生物相容性和成骨能力。结果表明,在植入后12周内,材料完全降解并吸收,形成了新的小梁骨和软骨组织。体内释放试验表明,RPM加载的BHA / PAA表现出利福纳州的持续释放曲线,并且肌肉组织中的药物浓度仍然高于二烷酸二淀粉的最小抑制浓度,只需12周即可长达12周。此外,RPM加载的BHA / PAA对治疗的兔子的心脏,肝脏和肾脏没有长期副作用。总之,本研究证明,RPM负载的BHA / PAA在体内缓慢而连续地释放二兆内,并对心脏,肝肾组织和功能表现出副作用。此外,RPM加载的BHA / PAA促进了新的骨形成,而逐渐降解和吸收。本研究为开发骨质骨质结核病新疗法的潜在进步提供了理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号